Related Experiment Video
Updated: May 24, 2025

Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
Dopamine Toxicity Induces ROS-Dependent Death of Murine Neuroblastoma Cells: Impact on the Interactions of Cofilin
Tapasi Roy1, Rachana Banerjee2, Abhishek Chatterjee1
1Infectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata, West Bengal, 700032, India.
Abstract:
The death of dopaminergic neurons, a hallmark event during Parkinson's disease (PD), leads to increased dopamine concentration in the neuronal micro-environment. Keeping this in mind, we intend to understand the impact of elevated dopamine concentration on molecular interactions among proteins and the stability of the neuronal cytoskeleton. We used differentiated N2A cells and exposed them to 100 µM DA for 24 h. Evaluations of cell death, measurement of the concentration of DA oxidation products and reactive oxygen species (ROS), conventional RT-PCR, western blotting, zymography, reverse zymography, co-immunoprecipitation, mitochondrial transmembrane potential, confocal imaging, and in-silico studies were performed thereon. We observed that a significant number of viable N2A cells underwent ROS-dependent apoptotic cell death under elevated media DA concentrations. An altered transcriptional pattern of alpha-synuclein, UCHL1, and cofilin genes and their respective gene products were also observed. The activity and expression of matrix metalloproteinases9 (MMP9), involved in neuro-inflammation, was enhanced upon DA-exposure. Further, DA exposure also led to degradation of actin cytoskeleton. In silico studies revealed that interactions of Cofilin with UCHL1 and MMP9 were altered in dopamine-rich microenvironment. This result was further validated by co-immunoprecipitation experiments. Collectively our observations with murine neuroblastoma cells suggest that DA toxicity alters interaction patterns among intracellular proteins and degrades neuronal cytoskeleton that finally leads to cell death. Our study unveils a new frontier in PD treatment by paving the way for the development of specific drugs targeting the DA altered protein interactions.
Insights
Elevated dopamine in Parkinson's disease causes cell death by damaging the neuronal cytoskeleton and altering protein interactions. This research opens new avenues for targeted drug development to combat the disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Parkinson's disease (PD) is characterized by dopaminergic neuron loss.
- This loss results in increased dopamine levels in the brain's micro-environment.
- The impact of this elevated dopamine on neuronal structures and protein interactions is not fully understood.
Purpose of the Study:
- To investigate the effects of high dopamine concentration on neuronal protein interactions and cytoskeleton stability.
- To elucidate the mechanisms underlying dopamine-induced neurotoxicity.
Main Methods:
- Murine neuroblastoma N2A cells were exposed to elevated dopamine (100 µM).
- Assays included cell death evaluation, reactive oxygen species (ROS) measurement, gene expression analysis (RT-PCR), protein analysis (Western blotting, co-immunoprecipitation), enzyme activity assays (zymography), mitochondrial potential assessment, and in-silico modeling.
- Confocal imaging was used to visualize cellular changes.
Main Results:
- Elevated dopamine induced ROS-dependent apoptotic cell death.
- Transcriptional and protein levels of alpha-synuclein, UCHL1, and cofilin were altered.
- Matrix metalloproteinases9 (MMP9) activity and expression increased, indicating neuro-inflammation.
- Actin cytoskeleton degradation and altered Cofilin-UCHL1/MMP9 interactions were observed, confirmed by in-silico and co-immunoprecipitation studies.
Conclusions:
- Dopamine toxicity in a Parkinson's disease-like environment disrupts intracellular protein interactions and degrades the neuronal cytoskeleton, leading to cell death.
- These findings suggest novel therapeutic strategies targeting dopamine-altered protein interactions for PD treatment.

